Clinical Trial Update: PIoglitazone for PrEvention of Restenosis in Diabetic Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial investigating pioglitazone for preventing restenosis in patients with diabetes; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Restenosis
• Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: University of Rome Tor Vergata | Conditions: Coronary Atherosclerosis, Coronary Restenosis | Phase 3 | Status: UNKNOWN